HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

Benzinga Newsdesk www.benzinga.com Negative 51.1%

Neg 51.1% Neu 0% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $185 to $140.